SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud

ARS Pharmaceuticals’ SPRY shares fell over 23% in after-hours trading on June 24, 2026 after the company disclosed that Neffy received no new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle. The update signals stalled coverage momentum, likely pressuring investor confidence. The article also prompts shareholders to pursue legal claims.

Analysis

This is an access story, not just a sentiment event. When a new rescue therapy fails to add payer doors, the market should re-rate it on slower revenue recognition, higher gross-to-net friction, and lower terminal penetration—not on near-term unit demand alone. That is usually bearish for the issuer and quietly supportive for entrenched alternatives with existing formulary position, because PBMs tend to favor incumbent utilization when the new product cannot clear coverage thresholds.

The first-order selloff may be too violent if positioning was crowded and the market had already assumed a near-term reimbursement cadence. But the second-order risk is real: each missed review cycle increases the probability that physicians sample but do not convert patients because cash-pay economics are poor for a chronic rescue product. Over the next 1-3 months, the key variable is whether management can secure a national or regional payer win that changes the script-to-revenue conversion rate; without that, valuation will likely compress again on the next commercial update.

Contrarian view: the consensus may be overstating the permanence of one missed cycle. Formulary decisions are lumpy and can reflect timing rather than rejection, so a sharp rebound is possible on any new coverage headline. The bear case only becomes durable if the next quarter shows no acceleration in paid access and no evidence that rebates/copay support can bridge the gap. That would turn this from an event-driven gap lower into a structural adoption problem.

Key Decisions for Investors

• Avoid initiating fresh long exposure in SPRY for now; wait 2-4 weeks for either a payer-addition headline or evidence of commercial script acceleration before paying up for a rebound.
• Tactically short SPRY on any bounce into the post-gap range over the next 1-3 months; stop the trade immediately if management announces a meaningful national PBM or regional formulary win.
• Relative-value expression: short SPRY vs. long an incumbent epinephrine autoinjector proxy such as TEVA or VTRS for 1-3 months, betting that access inertia favors the incumbent while reimbursement remains blocked.
• Use the next quarterly commercial print as the falsifier: if paid prescriptions and gross-to-net improve despite the missed cycle, cover bearish exposure; if not, the stock likely has another leg lower.